

Cristina Saura

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1579299/cristina-saura-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

81
papers

3,042
citations

26
h-index

55
g-index

91
ext. papers

4,520
ext. citations

9.2
avg, IF

4.65
L-index

#	Paper	IF	Citations
81	Abstract OT2-27-01: Solti-1718 NEREA Trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-enriched (HER2-E) advanced breast cancer (BC). <i>Cancer Research</i> , 2022 , 82, OT2-27-01-OT2-27-01	10.1	0
80	Abstract OT1-12-01: Solti-1804 HER2-PREDICT: Translational study of tumor samples from breast cancer patients treated with trastuzumab deruxtecan in the metastatic setting. <i>Cancer Research</i> , 2022 , 82, OT1-12-01-OT1-12-01	10.1	
79	Abstract P1-07-02: Primary results of ONAWA (SOLTI-1802) trial: A window of opportunity trial of onapristone in postmenopausal women with progesterone receptor-positive/HER2-negative early breast cancer (EBC). <i>Cancer Research</i> , 2022 , 82, P1-07-02-P1-07-02	10.1	0
78	Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis.. <i>Cancer Treatment Reviews</i> , 2022 , 104, 102362	14.4	2
77	A retrospective validation of CanAssist Breast in European early-stage breast cancer patient cohort.. <i>Breast</i> , 2022 , 63, 1-8	3.6	0
76	Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.. <i>Cancer Research</i> , 2022 , 82, 1646-1657	10.1	4
75	GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells. <i>Cancers</i> , 2022 , 14, 2562	6.6	1
74	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211053416	5.4	0
73	Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	5
72	Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and prior HER2-directed regimens. <i>Breast Cancer Research and Treatment</i> , 2021 , 188, 449-458	4.4	
71	SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 638482	5.3	5
70	Impact of circulating tumor DNA (ctDNA) detection on survival outcomes of patients (pts) treated with immune-checkpoint inhibitors (ICIs) in early clinical trials.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2542-2542	2.2	1
69	Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial. <i>Oncologist</i> , 2021 , 26, e1327-e1338	5.7	7
68	Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with -Mutant Cancers. <i>Clinical Cancer Research</i> , 2021 , 27, 447-459	12.9	13
67	Reply to T. J. A. Dekker, D.-C. Mo et al, and A. Seidman et al. <i>Journal of Clinical Oncology</i> , 2021 , 39, 254-255		
66	Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021 , 189, 377-386	4.4	4
65	Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. <i>EBioMedicine</i> , 2021 , 69, 103451	8.8	3

64	Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study. <i>Frontiers in Oncology</i> , 2021 , 11, 645026	5.3	1
63	Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3293-3305	2.2	14
62	Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. <i>Clinical Cancer Research</i> , 2021 , 27, 5607-5618	12.9	0
61	Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 5818-5827	12.9	3
60	High mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer. <i>Clinical Cancer Research</i> , 2021 ,	12.9	1
59	Clinical consequences of BRCA2 hypomorphism. <i>Npj Breast Cancer</i> , 2021 , 7, 117	7.8	0
58	Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials. <i>European Journal of Cancer</i> , 2021 , 155, 168-178	7.5	
57	Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. <i>Breast</i> , 2021 , 59, 327-338	3.6	5
56	Functional Mapping of AKT Signaling and Biomarkers of Response From the FAIRLANE Trial of Neoadjuvant Ipatasertib Plus Paclitaxel for Triple-Negative Breast Cancer.. <i>Clinical Cancer Research</i> , 2021 ,	12.9	4
55	Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	4
54	The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1. <i>Cancers</i> , 2020 , 12,	6.6	14
53	Breast cancer during pregnancy: matched study of diagnostic approach, tumor characteristics, and prognostic factors. <i>Tumori</i> , 2020 , 106, 378-387	1.7	1
52	Efficacy and Determinants of Response to HER Kinase Inhibition in -Mutant Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2020 , 10, 198-213	24.4	41
51	Association of T- and B-cell receptor repertoires with molecular subtypes and outcome in HER2+ breast cancer: An analysis of the NeoALTTO clinical trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 511-511 ^{2.2}		
50	Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 33-43	21.7	52
49	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 610-621	59.2	536
48	Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. <i>Lancet Oncology, The</i> , 2020 , 21, 1283-1295	21.7	62
47	Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With \geq HER2-Directed Regimens: Phase III NALA Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3138-3149	2.2	150

46	Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. <i>Breast Cancer Research</i> , 2020 , 22, 120	8.3	22
45	Sequential immunohistochemistry and virtual image reconstruction using a single slide for quantitative KI67 measurement in breast cancer. <i>Breast</i> , 2020 , 53, 102-110	3.6	2
44	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. <i>Lancet Oncology, The</i> , 2020 , 21, 1455-1464	21.7	20
43	Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 731-741	3.5	1
42	Circulating Tumor DNA and Biomarker Analyses From the LOTUS Randomized Trial of First-Line Ipatasertib and Paclitaxel for Metastatic Triple-Negative Breast Cancer.. <i>JCO Precision Oncology</i> , 2020 , 4, 1012-1024	3.6	3
41	Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. <i>Clinical Cancer Research</i> , 2020 , 26, 3720-3731	12.9	10
40	Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2019 , 5, 1556-1564	13.4	38
39	Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. <i>Lancet Oncology, The</i> , 2019 , 20, 1124-1135 ¹²⁷	21.7	127
38	Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 1226-1238	21.7	55
37	A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019 , 178, 121-133	4.4	4
36	POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2019 , 25, 6598-6605	12.9	11
35	Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1002-1002	2.2	61
34	Determinants of concordance in clinically relevant genes (CRG) from synchronously acquired tumor biopsies (tBx) and ctDNA in metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1075-1075 ²	2.2	2
33	Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement. <i>Oncologist</i> , 2019 , 24, 603-611	5.7	20
32	Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib. <i>Clinical Cancer Research</i> , 2019 , 25, 7381-7387	12.9	9
31	HER2-positive breast cancer: Current and new therapeutic strategies. <i>Breast</i> , 2018 , 39, 80-88	3.6	57
30	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. <i>Nature</i> , 2018 , 554, 189-194	50.4	388
29	MSK1 regulates luminal cell differentiation and metastatic dormancy in ER breast cancer. <i>Nature Cell Biology</i> , 2018 , 20, 211-221	23.4	71

28	Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1008-1008	2.2	19
27	A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1014-1014	2.2	29
26	Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. <i>Oncotarget</i> , 2018 , 9, 20617-20630	3.3	26
25	A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. <i>EMBO Molecular Medicine</i> , 2018 , 10,	12	85
24	Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 4380-4387	12.9	41
23	Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1360-1372	21.7	263
22	A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. <i>Cancer Discovery</i> , 2017 , 7, 102-113	24.4	105
21	A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 520-520	2.2	20
20	Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015 , 149, 151-61	4.4	40
19	Abstract P6-12-02: Phase Ib dose-escalation study of an Akt inhibitor ipatasertib (Ipat) in combination with docetaxel (Doc) or paclitaxel (Pac) in patients (pts) with metastatic breast cancer (MBC) 2015 ,		3
18	LOTUS: A randomized, phase II, multicenter, placebo-controlled study of ipatasertib (Ipat, GDC-0068), an inhibitor of Akt, in combination with paclitaxel (Pac) as front-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS1111-TPS1111	2.2	3
17	FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (Ipat, GDC-0068) in combination with paclitaxel (Pac) as neoadjuvant treatment for early stage triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS1112-TPS1112	2.2	1
16	Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3626-33	2.2	96
15	Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy. <i>Clinical Cancer Research</i> , 2014 , 20, 1935-45	12.9	108
14	Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068. <i>Clinical Cancer Research</i> , 2013 , 19, 6976-86	12.9	63
13	Multidisciplinary approach to breast cancer diagnosed during pregnancy: maternal and neonatal outcomes. <i>Breast</i> , 2013 , 22, 515-9	3.6	15
12	Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of β -tubulin expression as a predictive marker. <i>Oncologist</i> , 2013 , 18, 787-94	5.7	25
11	Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 2062-71	6.1	66

10	Molecular prescreening to select patient population in early clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2012 , 9, 359-66	19.4	52
9	A phase Ib study of the Akt inhibitor GDC-0068 with docetaxel (D) or mFOLFOX-6 (F) in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3021-3021	2.2	5
8	A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 508-508	3.3	14
7	PI3K pathway (PI3Kp) dysregulation and response to pan-PI3K/AKT/mTOR/dual PI3K-mTOR inhibitors (PI3Kpi) in metastatic breast cancer (MBC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 509-509	2.2	3
6	Presentation and treatment of HER2-positive metastatic breast cancer patients already treated with adjuvant trastuzumab.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 619-619	2.2	
5	Molecular profiling of patients (pts) with colorectal cancer (CRC) and matched targeted therapy (MTA) in phase I clinical trials.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3014-3014	2.2	
4	Prognostic significance of PI3K pathway (PI3Kp) dysregulation in metastatic breast cancer (MBC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 566-566	2.2	
3	Analysis of the intratumoral heterogeneity of PIK3CA mutant alleles in breast cancer (BC): Implications for the luminal (LUM) phenotype.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10511-10511	2.2	
2	Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. <i>British Journal of Clinical Pharmacology</i> , 2010 , 70, 656-63	3.8	81
1	Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005 , 28, 424	2.7	1